Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,otherCurrentAssets,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,changeToOperatingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,MOR.DE,508989036.0,32758600,32317104,,-56099926,,-41608233,38423732,42141636,-28599200,-28599200,,-2900000,,,,-14491693,47189617,75788817,5047981,-27500726,,-41608233,-41608233,69044695.0,749845501.0,1070252524.0,579652964.0,73936851.0,1649905488.0,32890046.0,-199497443.0,551360092.0,1619233.0,-3585140.0,146229814.0,109585940.0,202262615.0,144561684.0,923801.0,1283604.0,49922366.0,1257376211.0,125713169.0,761977612.0,104173351.0,275192962.0,13399992.0,124296820.0,,34000000.0,-2104354.0,33192421.0,-789054.0,11025823.0,-208740.0,-2206309.0,-42220675.0,2316258.0,20379.0,-63278.0,-16904156.0,11814877.0,16143088.0,-259069.0,,1055113596.0,en-US,US,EQUITY,False,Delayed Quote,50.74,1630578593,0.52000046,50.0,50.78,49.39,104191,EUR,GER,1662171392,7200000,False,False,REGULAR,2,1.035445,49.39 - 50.78,de_market,0,MORPHOSYS AG O.N.,50.22,50.7,50.78,15,88,finmb_135647,XETRA,MorphoSys AG,EUR,367193,356216,7.460003,0.17236607,43.28 - 117.9,-67.16,-0.56963533,43.28,117.9,1636560000,1636560000,1636560000,-4.254,-2.26,17.695,48.794,1.946003,0.039882015,67.690636,-16.950634,-0.25041327,-22.451328,2.867477,15,Europe/Berlin,CEST,0.81,,,117.9,43.28,48.79,67.69,367.19k,356.22k,32.76M,,32.7M,2.84%,60.42%,,,,,,,,,,,0.00%,,,3:1,"Dec 23, 2008","Dec 31, 2020","Mar 31, 2021",-112.59%,-160.22%,-8.30%,-22.31%,123.67M,3.78,-81.20%,318.52M,-192.95M,-139.23M,-4.25,,1.12B,34.26,320.66M,55.32,6.22,17.69,-216.92M,-142.96M,Value,82152,Healthcare,609,2,4,"MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",Planegg,49 89 89927 0,1,1609372800,1622505600,1,Germany,http://www.morphosys.com,86400,1,Semmelweisstrasse 7,49 89 89927 222,Biotechnology
t-1,MOR.DE,550327635.0,32758600,52494595,,-36715321,,-16525527,46972880,26626624,-72840851,-72840851,,-27410166,,,,-20189794,36044060,108884911,9417436,36125530,,-16525527,-16525527,69375149.0,748978506.0,1038191003.0,621322017.0,86503473.0,1659513020.0,32890046.0,-157889210.0,523008010.0,1619233.0,-2657325.0,134373356.0,109794680.0,200459229.0,132806097.0,422945.0,2211419.0,50741520.0,1206816220.0,196587542.0,692583841.0,89835577.0,272759970.0,9962657.0,47558635.0,10003493.0,-206949447.0,59171967.0,-214521179.0,319404121.0,330365012.0,45481237.0,-431186.0,-69181411.0,2663156.0,2664959.0,-8485396.0,-52949884.0,10960891.0,-59586366.0,-627684.0,6449639.0,1006356991.0,en-US,US,EQUITY,False,Delayed Quote,50.74,1630578593,0.52000046,50.0,50.78,49.39,104191,EUR,GER,1662171392,7200000,False,False,REGULAR,2,1.035445,49.39 - 50.78,de_market,0,MORPHOSYS AG O.N.,50.22,50.7,50.78,15,88,finmb_135647,XETRA,MorphoSys AG,EUR,367193,356216,7.460003,0.17236607,43.28 - 117.9,-67.16,-0.56963533,43.28,117.9,1636560000,1636560000,1636560000,-4.254,-2.26,17.695,48.794,1.946003,0.039882015,67.690636,-16.950634,-0.25041327,-22.451328,2.867477,15,Europe/Berlin,CEST,0.81,,,117.9,43.28,48.79,67.69,367.19k,356.22k,32.76M,,32.7M,2.84%,60.42%,,,,,,,,,,,0.00%,,,3:1,"Dec 23, 2008","Dec 31, 2020","Mar 31, 2021",-112.59%,-160.22%,-8.30%,-22.31%,123.67M,3.78,-81.20%,318.52M,-192.95M,-139.23M,-4.25,,1.12B,34.26,320.66M,55.32,6.22,17.69,-216.92M,-142.96M,Value,82152,Healthcare,609,2,4,"MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",Planegg,49 89 89927 0,1,1609372800,1622505600,1,Germany,http://www.morphosys.com,86400,1,Semmelweisstrasse 7,49 89 89927 222,Biotechnology
t-2,MOR.DE,535589622.0,32758600,34177265,,-97217247,,-65344755,46126113,18272642,-62030736,-62030736,,-67574320,,,,-31872492,21997678,84028414,3725036,-35186511,,-65344755,-65344755,58772638.0,711495523.0,782109301.0,598038493.0,93296431.0,1380147794.0,32890046.0,-141363683.0,568230763.0,3676233.0,-4983393.0,152312750.0,64313443.0,170874957.0,150729321.0,,598863.0,52110567.0,858435183.0,254840423.0,452512240.0,39926393.0,,15236976.0,74430899.0,,95605642.0,22498216.0,73151100.0,-1011176.0,-42350.0,30909092.0,3111160.0,-45310817.0,1888475.0,1118453.0,-8485396.0,1351450.0,968826.0,-3116444.0,-2323211.0,-2587759.0,687560226.0,en-US,US,EQUITY,False,Delayed Quote,50.74,1630578593,0.52000046,50.0,50.78,49.39,104191,EUR,GER,1662171392,7200000,False,False,REGULAR,2,1.035445,49.39 - 50.78,de_market,0,MORPHOSYS AG O.N.,50.22,50.7,50.78,15,88,finmb_135647,XETRA,MorphoSys AG,EUR,367193,356216,7.460003,0.17236607,43.28 - 117.9,-67.16,-0.56963533,43.28,117.9,1636560000,1636560000,1636560000,-4.254,-2.26,17.695,48.794,1.946003,0.039882015,67.690636,-16.950634,-0.25041327,-22.451328,2.867477,15,Europe/Berlin,CEST,0.81,,,117.9,43.28,48.79,67.69,367.19k,356.22k,32.76M,,32.7M,2.84%,60.42%,,,,,,,,,,,0.00%,,,3:1,"Dec 23, 2008","Dec 31, 2020","Mar 31, 2021",-112.59%,-160.22%,-8.30%,-22.31%,123.67M,3.78,-81.20%,318.52M,-192.95M,-139.23M,-4.25,,1.12B,34.26,320.66M,55.32,6.22,17.69,-216.92M,-142.96M,Value,82152,Healthcare,609,2,4,"MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",Planegg,49 89 89927 0,1,1609372800,1622505600,1,Germany,http://www.morphosys.com,86400,1,Semmelweisstrasse 7,49 89 89927 222,Biotechnology
t-3,MOR.DE,614581059.0,32758600,30932839,,-57987786,,-53088735,43095737,25661840,-48366736,-48366736,,-25076101,,,,-4899051,18434036,66800772,-7227804,-9621050,,-53088735,-53088735,38255574.0,710306493.0,767592602.0,656512866.0,114360831.0,1424105468.0,32890046.0,-76018928.0,551982016.0,3676233.0,-10664745.0,146216657.0,33404351.0,171619276.0,145109528.0,,-4280863.0,51569543.0,927927372.0,256460089.0,432783413.0,36658166.0,,15330267.0,54138646.0,,-524706183.0,6253888.0,-527563212.0,-625011.0,-1087734.0,-587415428.0,1437636.0,-60202118.0,1847412.0,-2010850.0,-8485396.0,-7273558.0,-462723.0,-37672021.0,-790622.0,-7606352.0,756308096.0,en-US,US,EQUITY,False,Delayed Quote,50.74,1630578593,0.52000046,50.0,50.78,49.39,104191,EUR,GER,1662171392,7200000,False,False,REGULAR,2,1.035445,49.39 - 50.78,de_market,0,MORPHOSYS AG O.N.,50.22,50.7,50.78,15,88,finmb_135647,XETRA,MorphoSys AG,EUR,367193,356216,7.460003,0.17236607,43.28 - 117.9,-67.16,-0.56963533,43.28,117.9,1636560000,1636560000,1636560000,-4.254,-2.26,17.695,48.794,1.946003,0.039882015,67.690636,-16.950634,-0.25041327,-22.451328,2.867477,15,Europe/Berlin,CEST,0.81,,,117.9,43.28,48.79,67.69,367.19k,356.22k,32.76M,,32.7M,2.84%,60.42%,,,,,,,,,,,0.00%,,,3:1,"Dec 23, 2008","Dec 31, 2020","Mar 31, 2021",-112.59%,-160.22%,-8.30%,-22.31%,123.67M,3.78,-81.20%,318.52M,-192.95M,-139.23M,-4.25,,1.12B,34.26,320.66M,55.32,6.22,17.69,-216.92M,-142.96M,Value,82152,Healthcare,609,2,4,"MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.",Planegg,49 89 89927 0,1,1609372800,1622505600,1,Germany,http://www.morphosys.com,86400,1,Semmelweisstrasse 7,49 89 89927 222,Biotechnology
